Hideho Okada

Department of Neurological Surgery, University of California, San Francisco

Affiliated withUniversity of California, San Francisco

Research Area

Biography

Hideho Okada has not added Biography.
If you are Hideho Okada and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 1	2024

Other Publications

Article	Year
Classification of current anticancer immunotherapies. Oncotarget\| PubMed ID: 25537519	2014
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. Journal for immunotherapy of cancer\| PubMed ID: 25598973	2014
Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. Biochemical and biophysical research communications\| PubMed ID: 25677619	2015
Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC). Journal for immunotherapy of cancer\| PubMed ID: 25746013	2014
Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy. Oncoimmunology\| PubMed ID: 26137417	2015
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. The Lancet. Oncology\| PubMed ID: 26545842	2015
IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro-oncology\| PubMed ID: 27116977	2016
Cellular immunotherapy for malignant gliomas. Expert opinion on biological therapy\| PubMed ID: 27434205	2016
Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine. Scientific reports\| PubMed ID: 27507680	2016
Is the immune response a friend or foe for viral therapy of glioma? Neuro-oncology\| PubMed ID: 28874006	2017
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. The Journal of experimental medicine\| PubMed ID: 29203539	2018
Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model. Scientific reports\| PubMed ID: 29255242	2017
Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome biology\| PubMed ID: 29262845	2017
Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. Oncoimmunology\| PubMed ID: 29308320	2018
Immunotherapy of Primary Brain Tumors: Facts and Hopes. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 29871908	2018
Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine-19 MRI detection. Magnetic resonance in medicine\| PubMed ID: 31631402	2020
Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy. Journal of neuro-oncology\| PubMed ID: 31728884	2020
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy). Journal for immunotherapy of cancer\| PubMed ID: 31783779	2019
Tumor antigens in glioma. Seminars in immunology\| PubMed ID: 32037183	2020
T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment. Journal of neuro-oncology\| PubMed ID: 32185647	2020
Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Neuro-oncology practice\| PubMed ID: 33014387	2020
Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert review of neurotherapeutics\| PubMed ID: 33225764	2021
Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. JCI insight\| PubMed ID: 33232299	2021
Current Advances in Immunotherapy for Glioblastoma. Current oncology reports\| PubMed ID: 33496872	2021
Assessing Oximetry Response to Chimeric Antigen Receptor T-cell Therapy against Glioma with F MRI in a Murine Model. Radiology. Imaging cancer\| PubMed ID: 33575659	2021
SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Science translational medicine\| PubMed ID: 33910979	2021
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. Journal for immunotherapy of cancer\| PubMed ID: 34083417	2021
IFN-γ- and IL-17-producing CD8 T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity. Journal for immunotherapy of cancer\| PubMed ID: 34193567	2021
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. Journal for immunotherapy of cancer\| PubMed ID: 35606087	2022
The future of cancer immunotherapy for brain tumors: a collaborative workshop. Journal of translational medicine\| PubMed ID: 35606815	2022
RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature\| PubMed ID: 36002574	2022
Magnetic Resonance Spectroscopy Metabolites as Biomarkers of Disease Status in Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) Treated with Glioma-Associated Antigen Peptide Vaccines. Cancers\| PubMed ID: 36497477	2022
Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch . Journal for immunotherapy of cancer\| PubMed ID: 36944450	2023
Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma. Cancer discovery\| PubMed ID: 37378557	2023
Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell\| PubMed ID: 38242087	2024
Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in glioma. Scientific reports\| PubMed ID: 38493204	2024
IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma. bioRxiv : the preprint server for biology\| PubMed ID: 38617245	2024
A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives. Cells\| PubMed ID: 38727262	2024
IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma. Neuro-oncology\| PubMed ID: 39115195	2024
Activating the dark genome to illuminate cancer vaccine targets. Nature genetics\| PubMed ID: 39223317	2024